Trinutra Ltd.

Pharmatwob Ltd.

Mapi Pharma Ltd.

Lycored Bio Ltd.

Given Imaging Ltd.

4p-pharma

Yoram Sela

Itschak Lamensdorf

Mor Zeilkha

Ehud Marom

Shai Rubnov

Raphael Rabinovitz

Nadav Bleich Kimelman

Nurit Livnah

Yehudit Kraizer

Tomer Madmon

The present invention provides a composition comprising a synergistic combination of thymoquinone and one or more omega-3 fatty acids, wherein the molar ratio between said thymoquinone and said one or more omega-3 fatty acids is at least 1:7. The present invention also provides a method of using said composition to treat or prevent inflammatory conditions.

Compositions comprising thymoquinone and omega-3 fatty acids

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine,, and &#x3b2;-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

Synergistic combinations of caffeine, ginkgo biloba and beta-phenylethylamine

The present invention provides an abuse deterrent oral fixed-dose composition, comprising a stimulant or opioid and an abuse deterrent active, wherein the abuse deterrent active is configured to be bioavailable only when the composition is crushed, ground or dissolved.

Stimulant abuse-deterrent compositions

The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.

Extended release dosage forms of pregabalin

The present invention provides a composition comprising a synergistic combination of melatonin, valerenic acid and carnosic acid. The composition may be used in the treatment and prevention of several different disorders including inflammatory conditions, sleep disorders and anxiety. The invention also relates to several dosage forms which are suitable for the delivery of the claimed composition to subjects in need of treatment therewith.

Compositions comprising melatonin

The present invention provides Glatiramer acetate compositions in a non-gelling matrix, formulated for sublingual delivery.

Sublingual delivery of glatiramer acetate

The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.

Extended release formulations of rasagiline and uses thereof

Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release.

Pharmaceutical compositions for treatment of Parkinson's disease

Pharmaceutical compositions for treatment of Parkinsons disease

The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.

Extended release compositions comprising as active compound venlafaxine hydrochloride

A device and method is described for enabling an examining device to pass through an abnormally configured body lumen. The device may pass through a body lumen while maintaining an initial dimension. Upon encounter with an abnormally configured body lumen, the device may be depleted and take on a final dimension after a predetermined time period, regardless of its current orientation with respect to the body lumen, so that the device may pass through and vacate the abnormally configured body lumen shortly after the predetermined time period may have elapsed.

Growing community of inventors

Raanana, Israel

Yoram Sela